February 21, 2024

fatido/iStock via Getty Images

TScan Therapeutics (NASDAQ:TCRX) has been able to report positive results from its phase 1 multi-arm study for the treatment of patients with several types of hematological malignancies such as acute myeloid leukemia [AML], myelodysplastic syndrome [MDS] and Acute Lymphocytic Leukemia [ALL]. It did so